Skip to main content

Table 4 Results of subgroup analyses on OS and RFS

From: Prognostic value of circulating tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis

Variable OS RFS
n HR (95% CI) P-valuea I2 P-valueb n HR (95% CI) P-valuea I2 P-valueb
Yearc
 > Median 2 2.93 (1.62,5.31) <0.001 0% 0.7 1 4.04 (1.86,8.78) <0.001
 ≤ Median 6 2.78 (1.79,4.30) <0.001 0% 43% 2 5.48 (2.54,11.79) <0.001 0% 0.59
Country
 East Asia 4 3.34 (1.58,7.09) 0.002 12% 0.33 0
 non-East Asia 4 2.68 (1.76,4.08) <0.001 0% 0.69 3 4.71 (2.73,8.13) <0.001 0% 0.75
Patient no.d
 >Median 4 2.89 (1.93,4.31) <0.001 0% 0.96 1 5.06 (2.23,11.48) <0.001
  ≤ Median 4 2.89 (1.03,8.13) 0.04 37% 0.19 2 4.45 (2.15,9.24) <0.001 0% 0.47
Sampling time
 Baseline 7 2.85 (2.00,4.07) <0.001 0% 0.54 3 4.71 (2.73,8.13) <0.001 0% 0.75
 intra-therapy 1 2.04 (0.18,23.12) 0.56 0
Cutoff value
  ≥ 1/7.5 ml 4 2.89 (1.93,4.31) <0.001 0% 0.96 3 4.71 (2.73,8.13) <0.001 0% 0.75
  ≥ 2/7.5 ml 4 2.89 (1.03,8.13) 0.04 37% 0.19 0
Positive ratee
 >Median 4 2.09 (1.17,3.74) 0.01 0% 0.91 1 4.04 (1.86,8.78) <0.001
  ≤ Median 4 3.38 (2.17,5.26) <0.001 0% 0.41 2 5.48 (2.54,11.79) <0.001 0% 0.59
Quality
 High 7 2.61 (1.82,3.75) <0.001 0% 0.95 3 4.71 (2.73,8.13) <0.001 0% 0.75
 Low 1 11.12 (2.51,49.26) 0.17 0
Overall 8 2.83 (1.99,4.03) <0.001 0% 0.65 3 4.71 (2.73,8.13) <0.001 0% 0.75
  1. aP-value for estimates of HR.
  2. bP-value for heterogeneity
  3. c The median year of Os and PFs was 2015 and 2018, respectively
  4. d The median patient number of Os and PFs was 41.5 and 76, respectively
  5. e The median positive rate of Os and PFs was 23.8 and 18%, respectively
  6. “-”: not available